PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NERA Economic Consulting raises concerns over DHSC’s Statutory Scheme

The proposed changes could limit patients’s access to treatments and clinical trials.

The National Economic Research Associates (NERA) Economic Consulting has raised concerns about the analysis, assumptions and approach taken by the Department of Health and Social Care (DHSC) in its proposed changes to the Statutory Scheme.

Commissioned by the Association of the British Pharmaceutical Industry (ABPI), the proposed changes for branded medicines could deter investment in developing, researching and launching new medicines in the UK – ultimately limiting patients’s access to treatments and clinical trials.

The NERA team found that the DHSC’s proposals were focused on one of three of its stated objectives, constraining the costs of branded medicines and undermining other key objectives.

Additionally, the proposals are likely to result in low-margin medicines being withdrawn from the UK market, and companies may also not locate clinical trials in the UK if perceived as unsupportive of innovation.

NERA said that the proposals are driven by the objective of constraining the growth of branded medicine sales to the NHS to a 2% annual growth gap, with no justification by the DHSC.

Additionally, NERA has deemed the DHSC’s Life Cycle Adjustment mechanism, which aims to implement even higher rebates in parts of the medicines market, to be ‘insufficiently competitive’.

It suggested that statutory scheme consultations should be reviewed by the Better Regulations Executive (BRE) to ensure proper independent scrutiny of the scheme.

George Anstey, senior managing director at NERA Economic Consulting, said: “The ability to make informed policy choices relies on an accurate picture of the cost and benefits of any decision. The findings set out in our report suggest that this consultation falls well short of this goal.

“DHSC should be held to a higher standard and be subject to greater independent scrutiny than is currently the case.”

Richard Torbett, chief executive at ABPI, said: “While we recognise the very acute financial constraints the government faces, left unchanged these proposals will do serious harm to the UK’s reputation as a global centre for life sciences.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026